Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Gallo: Systemic, Mucosal & Passive Immunity |
| Strategy: | Protein & peptide vaccines |
| Study Type: | Pre-Clinical NHP |
| Species: | Rhesus macaque |
| Stage: | Assays Completed |
| Study Start Date: | 2008-12-11 |
| Study Made Public: | 2013-07-25 |
Title
Immunogenicity and efficacy of rhFLSC vs gp120 vaccination in the rhesus macaque/SHIV model
Description
CAVD 240 is a non-human primate challenge study comparing the envelope-based subunit protein, rhFLSC, versus gp120, when combined with two different adjuvants (RC529, a TLR4 agonist; and Iscomatrix, a saponin-containing ISCOM.).
Sign in to see full information about this study and to download study data.
Products
rhFLSC Protein SHIV162p3 RC529 Iscomatrix GPI-0100 BaL gp120 rhesus CD4 D1D2 TatIntegrated data
NAb
Non-integrated data
No non-integrated data is available for this study.